Latest From Microbiotica Ltd.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.
Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.
With its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Company Type
- Parent & Subsidiaries
- Microbiotica Ltd.
- Senior Management
Mike Romanos, CEO
Trevor Lawley, PhD, CSO
Nigel Crockett, PhD, VP, Bus. Dev.
- Contact Info
Biodata Innovation Ctr., Wellcome Genome
Cambridge, CB10 1DR
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.